SCHEMBL12618019

SCHEMBL12618019

CCOC(=O)n1c(=O)[nH]c2cccc(CC(=O)Nc3nc(-c4ccc(Cl)cc4)cs3)c2c1=O

nearest known ligand 0.59

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
▸ TRPA1 O75762 16/20 0.59
▸ TRPV4 Q9HBA0 2/20 0.50
▸ RORC P51449 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12652521 0.94 TRPA1 (0.61) TRPA1TRPV4
SCHEMBL1799679 0.80 TRPA1 (0.61) TRPA1TRPV4RORC
SCHEMBL14479301 0.77 TRPA1 (0.74) TRPA1TRPV4
SCHEMBL14479300 0.76 TRPA1 (0.75) TRPA1TRPV4
SCHEMBL1799914 0.76 TRPA1 (0.63) TRPA1TRPV4
SCHEMBL12618156 0.75 TRPA1 (0.84) TRPA1TRPV4
SCHEMBL13671691 0.74 TRPA1 (1.00) TRPA1TRPV4RORC
SCHEMBL13175031 0.73 TRPA1 (0.59) TRPA1TRPV4RORC
SCHEMBL1802172 0.73 PLA2G2A (0.46) —
SCHEMBL13075853 0.73 TRPA1 (0.54) TRPA1TRPV4RORC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7951814-B2 Quinazolinedione derivatives as TRPA1 modulators GLENMARK PHARMACEUTICALS, S.A. (CH) 2011-05-31 — — US disclosed
WO-2010004390-A1 QUINAZOLINE DIONE DERIVATIVES AS TRPA1 MODULATORS GLENMARK PHARMACEUTICALS, S.A. (CH) 2010-01-14 — — WO disclosed
US-20090325987-A1 QUINAZOLINEDIONE DERIVATIVES AS TRPA1 MODULATORS GLENMARK PHARMACEUTICALS, S.A. (CH) 2009-12-31 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090325987-A1 QUINAZOLINEDIONE DERIVATIVES AS TRPA1 MODULATORS TRPA1, TRPV1, TRPC3 TRPA1 1/4885TRPV4 6/4885RORC 557/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback